Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to Earnings Call for financial results for the fourth quarter and full-year ending March 31, 2021.
Sun Pharma share price hits new 52-week high after getting licence to produce low-cost COVID-19 drug
US drugmaker Eli Lilly and Co. said it has issued royalty-free, non-exclusive voluntary licences to Sun Pharmaceutical Industries to produce its baricitinib drug in India to help combat the second wave of COVID-19 in India. Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Audited Standalone And Consolidated Financial Results Of The Company For The Fourth Quarter And Year Ended On March 31, 2021 And To Recommendation Of Final Dividend For The Year Ended March 31, 2021
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2021 ,inter alia, to consider and approve (i) Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2021. (ii) recommendation of final dividend for the year ended March 31, 2021 subject to the approval of the shareholders at the ensuing 29th Annual General Meeting.
Sun Pharma To Make Eli Lilly's Covid Medicine In India; Shares Gain
Sun Pharmaceutical shares rose as much as 3.51% to hit an intraday high of Rs 703.40 after it signed an agreement with Eli Lilly to make baricitinib. Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Sun Pharma signing a voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in India, SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 07, 2021 for Raksha Valia Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of loss of share certificates/request for issue of duplicate share certificate reported by shareholder of the Company, received from our Registrar and Transfer Agent, Link Intime India Private Limited on May 04, 2021. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
In furtherance to our intimation to the stock exchanges on 31st March 2021, that the partnership interest of one of the wholly owned Indian subsidiaries of Sun Pharmaceutical Industries Limited in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) stood revised from 20% to 12.5% entitling 12.5% share of profit/ loss and voting rights, we hereby intimate that post admission of 9 further new partners on 30th April 2021, in ABCD Technologies LLP, the partnership interest of our wholly owned Indian subsidiary in ABCD Technologies LLP now stands revised at 6.45% entitling 6.45% share of profit/ loss and voting rights. This is for your information and dissemination. Sun Pharmaceutical Industries Ltd - 524715 - Clarification / Confirmation On News Item
As per letter attached